



Alliance Neurooncology Committee Agenda

Friday, November 7, 2014

Open Session: 3:30 pm – 7:00 pm

Loews Chicago O'Hare Hotel

Alliance NeuroOnc Committee Call-in Information

Teleconference #: 1-800-501-8979

Access Code: 3057352

Welcome – Overview

E. Galanis

Active Protocols and Concepts in Development

Newly Diagnosed GBM

N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) [SAHA]Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma (Completed)

E. Galanis/P. Wen

N0877 Phase I Randomized Phase II Trial of Either Dasatanib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM) (Accrual goal met on 12/6/13)

E. Galanis

Phase I/II Study of AZD1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma

B. Alexander

A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation

J. Sarkaria

Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGHt)

B. Alexander

Overview of the Terry Fox Research Institute (TFRI) Program in Glioma Targeting

G. Cairncross
D. Senger/S. Robbins

New Concept: A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 in MGMT Unmethylated Newly Diagnosed Glioblastoma Following Resection and Chemoradiation.

P.Wen

Recurrent GBM

N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatanib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Accrual goal met on 3/27/14)	E. Galanis
A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)	A. Parsa
A071201: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme	E. Galanis/P.Wen
A071402: Phase II trial of the Aurora A Kinase Inhibitor MLN8237 in Recurrent Glioblastoma	B. Friday
New Concept: Randomized Phase II study of lomustine plus bevacizumab administered at standard versus reduced dosing for recurrent glioblastoma	D. Reardon

Anaplastic Gliomas – Newly Diagnosed

N0577 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma	K. Jaeckle
EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial	K. Jaeckle

Low Grade Gliomas

E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (Temp. Closed)	D. Schiff
R0925: Natural History in Low Risk LGG	P. Brown

Meningiomas

A0711401: Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations	P. Brastianos
--	---------------

Brain Metastases

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT)
(Accrual goal met on 11/8/13) P. Brown

N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases P. Brown

Symptom Control

A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme A. Porter

A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis after Radiosurgery: A Randomized Phase II Trial C. Chung